KR20220147238A - Composition for prevention, treatment or improvement of metabolic syndrome-related diseases comprising Soybean cultivar Cheongja5ho - Google Patents

Abstract

The present invention relates to a pharmaceutical composition comprising soybean cultivar Cheonja 5 as an active ingredient for preventing or treating metabolic syndrome-related diseases, a method for preventing or treating metabolic syndrome-related diseases by using the same, a health function food composition comprising soybean cultivar Cheonja 5 as an active ingredient for preventing or treating metabolic syndrome-related diseases, or a feed composition. The composition comprising soybean cultivar Cheonja 5 according to the present invention has effects of weight loss of a mouse consuming a high-fat diet, a reduction in weight of fats in a liver and epididymis, a reduction in blood lipid content, improvement of liver function, a reduction in fasting blood sugar, and a reduction in body fat, so that the composition can be useful for preventing, treating or alleviating metabolic syndrome-related diseases, resulting in inhibition of obesity and improvement of blood lipid. Therefore, the composition can be used as a medicine, a functional health food, and the like.

Description

Composition for prevention, treatment or improvement of metabolic syndrome-related diseases comprising Soybean cultivar Cheongja5ho, comprising soybean celadon No. 5 as an active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating metabolic syndrome-related diseases comprising bean variety celadon No. 5 as an active ingredient, a method for preventing or treating metabolic syndrome-related diseases using the composition; A health functional food composition for the prevention or improvement of metabolic syndrome-related diseases comprising soybean variety celadon No. 5 as an active ingredient; quasi-drug composition; or to a feed composition.

In recent years, the dietary fat intake of Korean adults has steadily increased, and according to the results of the National Health and Nutrition Examination Survey conducted in 2005, the rate of caloric intake from fat in Korean adults exceeds 20%. In particular, it was found that the increase in animal food intake was remarkable. Due to these changes in the eating pattern of Koreans, total fat intake and saturated fatty acid intake are increasing, raising concerns about health. This is because levels are an important determinant influencing blood lipid levels, and this diet has been shown to be associated with an increased risk of cardiovascular disease.

Furthermore, in the case of circulatory system diseases such as arteriosclerosis, myocardial infarction and stroke, it has been reported that in 2008, Koreans accounted for the second (cerebrovascular disease) and third (cardiovascular disease) causes of death. It is known that circulatory system diseases such as stroke are more affected by diet than other chronic diseases, and risk factors include blood cholesterol, blood triglycerides, high blood pressure, smoking, blood clots, diabetes, and obesity. Since cholesterol and high blood pressure are major risk factors for the occurrence of arteriosclerosis and myocardial infarction, it can be said that maintaining a normal blood cholesterol concentration is important in preventing the onset of the above diseases.

On the other hand, when cholesterol is properly controlled in the body, cholesterol accumulation does not occur in plasma and tissues, but when the level of cholesterol in the body rises, hypercholesterolemia appears and abnormality in cholesterol metabolism occurs, such as LDL and HDL cholesterol. The composition changes quantitatively. In particular, LDL-cholesterol among blood cholesterol is known as a risk factor for cardiovascular disease, and an increase in blood triglyceride concentration lowers the concentration of HDL-cholesterol and increases the content of chromic micron residues, which is the main cause of coronary artery disease. (Goldberg, I.J., J. Lipid Res., 37, pp693-707, 1996), blood lipids pass through vascular endothelial cells better than other lipids, so they are the main cause of atherosclerosis and rapid triglycerides after eating. It has been reported that an increase in cerebral palsy is closely related to the occurrence of stroke (Feldman, R.G. and Albrick, M.J., S. Arch. Neurol., 10, pp91, 1964). On the other hand, HDL-cholesterol has the effect of removing cholesterol from the blood vessel wall, so it is reported as a preventive factor for cardiovascular disease.

Therefore, in order to prevent or treat metabolic syndrome-related diseases, it is important to maintain normal concentrations of each component of blood lipids composed of triglycerides, cholesterol, phospholipids and free fatty acids in vivo.

Currently, as a treatment method used to prevent and treat metabolic syndrome-related diseases by appropriately controlling the concentration of lipid components in the blood, a diet that mainly recommends intake of dietary fiber, saponin, vitamin C, vitamin E, and essential amino acids is However, in the case of diet, there is a problem that it is difficult to continue for a long time because it is accompanied by mental illness due to dietary restriction.

In addition to the above diet, drug therapy is used for the treatment of metabolic syndrome-related diseases. In the case of such a lipid-lowering drug, it must be administered for life, and there is a risk of complications such as elevation of liver function and muscle disease, and in particular, liver function level. Since there is a problem in that it is difficult to treat with a drug when the value is increased more than 3 times, the need for research on useful active ingredients that can treat metabolic syndrome-related diseases among natural ingredients is emerging.

Therefore, as the number of obese people increases due to a change in eating habits, interest in food intake that can prevent this is increasing, and beans are known for the treatment of cardiovascular diseases (Korean Patent Application Laid-Open Publication No. KR 10-2011-0093730 A), but soybean varieties There is nothing known about the use of Celadon No. 5 for the prevention or treatment of metabolic syndrome-related diseases.

Under this background, as a result of the inventors' earnest efforts to obtain substances having a preventive or therapeutic effect on metabolic syndrome-related diseases from natural products, soybean variety Celadon No. 5 has superior functionality compared to existing soybean varieties, obesity suppression, metabolic syndrome treatment, The present invention was completed by verifying the prevention or improvement effect through mouse experiments.

One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of metabolic syndrome-related diseases comprising the soybean variety celadon No. 5 as an active ingredient.

Another object of the present invention is to provide a health functional food composition for the prevention or improvement of metabolic syndrome-related diseases comprising the soybean variety celadon No. 5 as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition for the prevention or improvement of metabolic syndrome-related diseases comprising soybean variety Celadon No. 5 as an active ingredient.

Another object of the present invention is to provide a feed composition for preventing or improving metabolic syndrome-related diseases comprising soybean variety Celadon No. 5 as an active ingredient.

As one aspect for achieving the above object, the present invention provides a pharmaceutical composition for preventing or treating metabolic syndrome-related diseases comprising the soybean variety celadon No. 5 as an active ingredient.

In the present invention, the term "Cheongja5ho" is one of the soybean (Glycine max (L.) Merrill) varieties, the yield is higher than the standard variety (Cheongja No. 3), the disaster resistance is similar, is low, the mosaic virus has strong characteristics, and the variety name registration application was announced on April 15, 2018 with the variety application notice number 'Name 2018-523', and on May 16, 2018, registration number 01-0003- It is a registered breed as No. 214.

Specifically, it is a seed characteristic of black green cotyledon, and artificially crossed in 2007 with 'Miryang No. 181' and 'YS1886' as the parent, giving the union number YS2000, and cultivating F1 and F2 generations in '08-'09, ' YS2000-2B-11-5-1-2-1 was selected by developing the F-F5 line in 10-'12. In the productivity test conducted between '13 and '14, it was regarded as a promising resource for the black cotyledon, which is a mature species, and gave the phylogenetic name 'Miryang No. 294'. This thick, uniform and strong characteristic of narrow cleavage showed that it was decided as a newly registered variety by the new variety selection committee for job training in December 2017 and named 'Celadon No. 5'.

In the present invention, the soybean variety Celadon No. 5 may be a Celadon No. 5 plant, a seed thereof, a dried product of the seed, an extract of the seed, or a fraction thereof, but is not limited thereto.

In the present invention, celadon No. 5 may mean that the plant of celadon No. 5 includes all plant parts such as roots, stems, leaves, flowers, and fruits (seeds), and specifically may be the seeds of celadon No. 5. The seeds may include seed coats.

In addition, in the present invention, celadon No. 5 may use a dried product of seeds or a powder state obtained by pulverizing the dried product. In addition, it may include an extract of the celadon seed No. 5 or a fraction thereof. The celadon No. 5 can be purchased commercially sold, or harvested or grown in nature.

As used herein, the term "metabolic syndrome-related disease" refers to various diseases caused by problems with metabolism, and is also referred to as metabolic disease. Metabolic syndrome-related diseases of the present invention include, without limitation, diseases that can be treated or prevented with soybean variety Celadon No. 5 as an active ingredient, but in the group consisting of obesity, hypertension, fatty liver, diabetes, dyslipidemia, hyperlipidemia, and arteriosclerosis. It may be one or more selected diseases.

As used herein, the term “obesity” refers to a condition or disease having excessive body fat due to energy imbalance. Although the cause of obesity is not clearly identified, it is a biological phenomenon caused by the interaction of complex genetic, metabolic, environmental, and behavioral factors and is generally recognized as overweight. Medically, if the body mass index (BMI) is 30 or more (30% or more of the standard body weight) or the BMI is 27 or more, other circulatory diseases such as diabetes, hypertension, hyperlipidemia, etc. are related. Those who are obese are classified as obese.

As used herein, the term "hyperlipidemia" refers to a disease caused by a large amount of fat in the blood because fat metabolism such as triglycerides and cholesterol is not properly performed. Specifically, as a state in which lipid components such as triglycerides, LDL cholesterol, phospholipids and free fatty acids in the blood are increased, hypercholesterolemia or hypertriglyceridemia with high incidence may be included.

In the present invention, the term "hardening of the arteries" refers to the accumulation of fatty substances (plaque) containing cholesterol, phospholipids, calcium, etc. in the intima of blood vessels, and the arteries become hard, lose elasticity and narrow, thereby inhibiting blood supply or increasing pressure, causing arteries to rupture or dissociate. It refers to the state in which the

As used herein, the term "hypertension" refers to a condition in which arterial blood pressure is chronically high, and refers to a case in which the systolic blood pressure is 140 mmHg or more or the diastolic blood pressure is 90 mmHg or more in adults 18 years of age or older, and may also be caused by obesity.

As used herein, the term "diabetes" refers to a disease that occurs when the secretion of insulin is insufficient or the action and function of insulin are not sufficiently achieved. It causes an abnormal increase in concentration, leading to diabetes and ketonuria, and pathological conditions such as circulation disorders and kidney disorders along with blood concentration due to electrolyte loss due to abnormal water and electrolyte metabolism. Insulin is secreted from the beta cells of the islets of Langerhans present in the pancreas, and is secreted when the blood glucose concentration increases, and when the blood glucose concentration decreases, the secretion is suppressed, thereby regulating the proper activity of the energy source. This disease is divided into insulin-dependent diabetes mellitus (type I) and non-insulin-dependent diabetes mellitus (type II). Diagnosis of diabetes is generally possible through measurement of blood glucose concentration, but there is a difference according to the criteria. In humans, diabetes is generally diagnosed when the blood glucose level is 200 mg/dl or more in normal blood and 140 mg/dl or more in fasting. Therefore, lowering the glucose concentration in the blood or liver can treat or prevent diabetes.

As used herein, the term "fatty liver" refers to a phenomenon in which triglycerides are abnormally deposited in liver cells, unlike normal cases. About 5% of the normal liver is composed of adipose tissue, and triglycerides, fatty acids, phospholipids, cholesterol, and cholesterol esters are the main components of fat. If it is more than 5% of the liver weight, it is diagnosed as fatty liver. Fatty liver is caused by disorders in fat metabolism in hepatocytes or defects in the process of transporting excess fat, and is mainly caused by disorders in fat metabolism in the liver. Most of the fat accumulated in the fatty liver is triglyceride, and fatty liver can be largely divided into non-alcoholic fatty liver caused by obesity, diabetes, hyperlipidemia, drugs, and the like, and alcoholic fatty liver caused by excessive drinking. The non-alcoholic fatty liver refers to a case accompanied by fatty liver without a history of alcohol intake, and is known to be related to metabolic diseases such as obesity, diabetes, and hyperlipidemia. The non-alcoholic fatty liver includes not only the accumulation of fat in the liver, but also non-alcoholic steatohepatitis or end-stage fibrotic liver disease. Fatty liver is known to be mostly related to obesity, but it is also a disease that can appear in skinny or normal people. This is supported by the report that 40% (32/81) of patients with fatty liver had a normal body mass index (Nucl. Med. Mol. Imaging., 40, 243 to 248 (2006)). In particular, it was reported that triglycerides act as a major factor in the non-obese group (J. Clin. Gastroenterol., 40, 745 ~ 752 (2006)), and the cholesterol and triglyceride levels in patients with fatty liver compared to the normal group was statistically significantly higher, indicating that the association between fatty liver and triglyceride was high in non-obese cases.

As used herein, the term “dyslipidemia” refers to a condition in which the blood contains an excessive amount of lipids or fat components due to increased biosynthesis or reduced degradation of lipoproteins carrying cholesterol and triglycerides, and as a result, total Cholesterol, LDL cholesterol, and triglycerides are elevated or HDL cholesterol is decreased.

It may be caused by genetic factors, obesity, diabetes, or drinking, but in particular, due to an increase in blood lipids due to a diet high in fat content, dyslipidemia may occur. Recently, as an alternative therapy using active ingredients derived from natural products such as herbal medicines and foods, or as a method for producing various extracts, a composition for hyperlipidemia treatment (Korean Patent Publication No. 2015-0064400), etc. has been developed, but the existing synthetic pharmaceutical The development of a natural pharmaceutical composition or a raw material thereof having a superior therapeutic effect and less side effects than the composition is still insufficient.

As used herein, the term "treatment" refers to any action of inhibiting or delaying metabolic syndrome-related diseases by administering a composition comprising the soybean variety Celadon No. 5 as an active ingredient.

As used herein, the term "prevention" refers to any action in which the symptoms of metabolic syndrome-related diseases are improved or beneficially changed by administration of a composition comprising the soybean variety Celadon No. 5 as an active ingredient.

In a specific embodiment of the present invention, weight loss, liver function improvement and blood triglycerides, total cholesterol, and fasting blood sugar were all reduced in the high fat-celadon group 5 (HFD-CJ) compared to the high fat diet group (HFD) among the experimental animals. It was confirmed, and a decrease in the amount of body fat was confirmed along with a decrease in the adipose tissue weight of the liver and epididymis. These results suggest that it can be usefully used for the prevention, treatment or improvement of metabolic syndrome-related diseases.

In addition, the pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition, wherein the carrier includes a non-naturally occurring carrier. can do. Specific examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil may be used, but is not limited thereto.

In addition, the pharmaceutical composition can be prepared according to a conventional method for each tablet, pill, powder, granule, capsule, suspension, internal solution, emulsion, syrup, sterilized aqueous solution, non-aqueous solution, suspension, emulsion, freeze-dried agent and suppository. It may have any one formulation selected from the group consisting of, and may be oral or parenteral various formulations. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Tablets, pills, powders, granules, capsules, etc. may be used in the solid preparation for oral administration, and the solid preparation may include at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, Gelatin or the like may be used. In addition to simple excipients, lubricants such as magnesium stearate and talc may be used. As liquid formulations for oral administration, suspensions, internal solutions, emulsions, syrups, etc. may be used, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be used. can be used A sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, a freeze-dried formulation, or a suppository may be used as a formulation for parenteral administration. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, etc. may be used, but is not limited thereto.

Another aspect provides a method for preventing or treating metabolic syndrome-related diseases, comprising administering the composition to an individual.

In this case, the definitions of "metabolic syndrome-related disease", "prevention" and "treatment" are the same as described above.

As used herein, the term “administration” refers to introducing the pharmaceutical composition to a subject by an appropriate method.

As used herein, the term "individual" refers to all animals, such as rats, mice, and livestock, including humans, that have or can develop metabolic syndrome-related diseases. The animal may be a mammal, such as a cow, a horse, a sheep, a pig, a goat, a camel, an antelope, a dog, or a cat, in need of prevention or treatment of similar symptoms as well as humans, but is not limited thereto.

The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount.

As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level depends on the type and severity of the subject, age, sex, activity of the drug, Sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field.

The pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. In addition, single or multiple administration may be used. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.

In addition, the pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may vary depending on the condition and weight of the patient, and the disease. Although it varies depending on the degree, drug form, administration route and time, it may be appropriately selected by those skilled in the art. As a specific example, the pharmaceutical composition can generally be administered once to several times a day, but the preferred dosage is appropriate by those skilled in the art according to the individual's condition and weight, the degree of disease, drug form, administration route and period. can be chosen

Another aspect provides a food composition for the prevention or improvement of metabolic syndrome-related diseases comprising the soybean variety celadon No. 5 as an active ingredient.

In this case, the definitions of "Cheongja No. 5", "metabolic syndrome-related diseases" and "prevention" are the same as described above.

The food composition of the present invention can be consumed on a daily basis, and unlike general drugs, it has the advantage of not having side effects that may occur during long-term use of drugs by using natural substances as raw materials, for the purpose of preventing or improving metabolic syndrome related diseases. It can be very useful.

As used herein, the term “improvement” refers to any action that reduces a parameter related to a condition to be treated by ingestion of the food composition, for example, the severity of symptoms.

As used herein, the term "food" refers to meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages , vitamin complexes, health functional foods, and health foods, and includes all foods in the ordinary sense.

The health functional food is the same term as food for special health use, FoSHU. means food.

Here, 'function (sex)' refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological actions with respect to the structure and function of the human body. The health food means a food having an active health maintenance or promotion effect compared to general food, and the health supplement food means a food for the purpose of health supplementation. In some cases, the terms health functional food, health food, and health supplement may be used interchangeably.

Specifically, the health functional food is a food prepared by adding soybean variety Celadon No. 5 to food materials such as beverages, teas, spices, gum, and confectionery, or encapsulating, powdering, suspension, etc. It means to bring a specific effect, but unlike general drugs, it has the advantage that there are no side effects that may occur when taking the drug for a long time using food as a raw material.

The food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art.

In addition, the food composition may be prepared without limitation in various types of formulations as long as the formulations are recognized as food.

In addition, the food composition may further include a food pharmaceutically acceptable carrier, the type of carrier is not particularly limited and any carrier commonly used in the art may be used.

In addition, the food composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, and vision. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr); and amino acids such as lysine, tryptophan, cysteine, and valine.

In addition, the food composition includes a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), a disinfectant (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), an antioxidant (butylhydroxyanisole (BHA), butyl hydro Loxytoluene (BHT), etc.), coloring agents (tar pigments, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, etc.) , sodium, etc.), flavorings (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (flavors), film agents, gum base agents, foam inhibitors, solvents, improvers, etc. It may contain food additives. The additive may be selected according to the type of food and used in an appropriate amount.

Another aspect for the purpose of the present invention provides a quasi-drug for the prevention or improvement of metabolic syndrome-related diseases comprising the soybean variety celadon No. 5 as an active ingredient.

The definitions of “Celadon No. 5”, “metabolic syndrome-related diseases”, “prevention” and “improvement” are the same as described above.

The term "quasi-drug" as used in the present invention refers to articles that are not instruments, machines, or devices used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals, and pharmacologically affecting the structure and function of humans or animals. Articles used for the purpose of influencing, other than instruments, machines or devices, are meant.

In the present invention, the quasi-drug composition may have an effect of preventing or improving metabolic syndrome-related diseases, but is not limited thereto.

The quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent if necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a fragrance, a preservative, etc. may include

The "pharmaceutically acceptable carrier" may mean a carrier, excipient, or diluent that does not inhibit the biological activity and properties of the injected compound without irritating the organism, and specifically, non-naturally occurring carrier). The type of carrier usable in the present invention is not particularly limited, and any carrier commonly used in the art and pharmaceutically acceptable may be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. These may be used alone or in combination of two or more.

The composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral dosage forms, but preferably oral dosage forms, but is not limited thereto. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient to the compound, for example, starch, calcium carbonate, sucrose, lactose, It may be prepared by mixing gelatin or the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, Witepsol, Macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, etc. may be used.

The quasi-drug composition of the present invention may include, but is not limited to, disinfection cleaner, shower foam, ointment, wet tissue, coating agent, etc. may be appropriately selected from among the techniques of

As another aspect for achieving the above object, the present application provides a feed composition for preventing and improving metabolic syndrome-related diseases comprising the soybean variety celadon No. 5 as an active ingredient.

As used herein, the term "feed" may refer to any natural or artificial diet, one meal, etc., or a component of the one meal meal, for or suitable for the animal to eat, ingest, and digest.

The type of feed is not particularly limited, and feed commonly used in the art may be used. The composition for feed may include a feed additive. The feed additive of the present application corresponds to an auxiliary feed under the Feed Management Act, and may include probiotics. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton, or food. These may be used alone or may be used in combination of two or more.

The composition comprising the soybean variety celadon No. 5 of the present invention has the effect of reducing the weight of mice fed a high-fat diet, reducing the weight of liver and epididymal fat, reducing blood lipid content, improving liver function, reducing fasting blood sugar and reducing body fat, obesity It can be usefully used for the prevention, treatment or improvement of metabolic syndrome-related diseases, including inhibition and improvement of blood lipids, and thus can be used as pharmaceuticals, health functional foods, and the like.

1 shows the feeds of the normal diet group (Normal), the high-fat diet group (HFD), the high-fat-daewon bean group (HFD-DW), and the high-fat-celadon group 5 (HFD-CJ), which were used for breeding of experimental animals.
Figure 2 shows the weight change for 6 weeks of the experimental animals taking the soybean powder-added feed.
Figure 3 shows the final weight (body weight) after 6 weeks of the experimental animals taking the soybean powder-added feed.
4 shows the appearance of the liver according to the diet group immediately after organ extraction of experimental animals (a: normal diet group, b: high fat diet group, c: high fat-daewon bean group, d: high fat-celadon group No. 5).
5 is a comparison of the weight of epididymal fat according to the diet group of experimental animals.
6 is a comparison of the blood sugar content according to the dietary group of the experimental animals taking the feed for 6 weeks.

Hereinafter, the configuration and effect of the present invention will be described in more detail through embodiments of the present invention. These examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

Example 1. Breeding and dietary composition of experimental animals

The experimental animals used in the present invention were 40 C57BL/6 mice of 4 weeks of age received from Coretech (Pyeongtaek, Korea). The experimental animal breeding room was maintained at a temperature of 22 ± 1 °C, relative humidity of 50 ± 10%, and illumination at 150 ~ 300 lux, the light and dark cycle was set at 12 hour intervals, and water and feed were freely ingested.

After acclimatization for 1 week, all experimental animals were divided into 4 groups and reared separately for 6 weeks each, and the average body weight was the same. -DW) and high fat-celadon group 5 (HFD-CJ), and then an experimental diet (Dooyeol bio tech., Seoul, Korea) was prepared and supplied.

At this time, Daewon soybean and celadon No. 5 powder were provided and used by the Southern Crop Department of the National Academy of Food Sciences, Rural Development Administration. The normal diet group was fed PicoLab rodent diet 20, 5053 (Labdiet, St. Louis, USA), and the composition of the experimental diet group was D12492 (Research diet, Research Diets, New Brunswick, NJ, USA) was fed a partially modified high fat 60% diet, and to examine the weight loss effect of soybean powder, an experimental diet in which 50% of Daewon soybean and celadon 5 powder were added to a high-fat diet, respectively. It was prepared and fed (FIG. 1).

Water intake empirical formula composition table (g/100 g) Normal
(Normal diet) ¹⁾ HFD
(High-fat diet) ²⁾ HFD-DW
(High fat-Daewon soybean diet) ³⁾ HFD-CJ
(High fat-Celadon No. 5 diet) ⁴⁾ Casein 24.0 5.7 5.1 L-cystine 0.4 0.4 0.4 corn starch 0.0 0.0 0.0 Maltodextrin 10 15.0 3.1 3.3 Sucrose 8.3 8.7 8.7 Cellulose 13.2 0.0 0.0 Soybean oil 3.0 3.2 3.2 Lard 29.4 21.7 22.2 Mineral mix S10026 1.2 1.3 1.3 Dicalcium phosphate 1.6 1.7 1.6 Calcium carbonate 0.7 0.7 0.7 Potassium citrate, 1H ₂ O 2.0 2.1 2.1 Vitamin mix V 10001 1.2 1.3 1.3 Choline bitartrate 0.2 0.3 0.3 DW bean powder 0 50 0 CJ bean powder 0 0 50 Protein (kcal, %) 25 20 20 20 Carbohydrate (kcal, %) 62 20 20 20 Fat (kcal, %) 13 Total 100 100 100 100

1) Nutrient composition of Normal diet was provided from the company.

2) HFD: High fat 60% diet

3) HFD-DW: HFD+Daewon bean powder 50%

4) HFD-CJ: HFD+Chungja 5 powder 50%

During the breeding period, body weight and food intake were measured once a week and twice a week at a fixed time, respectively, and food intake was calculated by measuring the amount of food fed and the remaining amount. was calculated as the ratio of (FER=body weight gain (g)/food intake (g)). Fasting blood glucose was measured after fasting for 12 hours before sacrifice. This experiment was approved by the Animal Ethics Committee of Hanyang University (approval number: 2020-0169A), and was bred and tested according to the animal experiment handling regulations of the committee.

Example 2. Measurement of fasting blood glucose in laboratory animals, sacrifice and organ harvesting

After the experimental animals of Example 1 were fasted for 12 hours before sacrifice, blood was taken from the tail vein and fasting blood glucose was measured using AccuCheck (Roche Diagnostics, Indianapolis, IN, USA). In addition, intraperitoneal injection anesthesia was performed by mixing 100 mg/kg ketamine (Yuhan Co., Seoul, Korea) and 10 mg/kg xylazine (Bayer Korea, Seoul, Korea). After centrifugation at 3,000 x g for 15 minutes, serum was separated and used as an analysis sample.

In addition, the liver and epididymal fat (left/right) were extracted immediately after blood collection, rinsed with physiological saline, and then the weight was measured by removing moisture from the surface.

Example 3. Analysis of blood lipid content and liver function index

Using the serum isolated in Example 2, triglyceride (TG), total cholesterol (TC), and high density lipoprotein cholesterol (HDL-C) were analyzed using an automatic blood biochemical test analyzer (Fujifilm). , Tokyo, Japan). In addition, liver function indicators aspartate transaminase (AST) and alanine transaminase (ALT) were measured using a commercially available kit (Asan Pham., Seoul, Korea).

Example 4. Analysis of body composition through a bilateral irradiation device (DEXA)

After 6 weeks of experimental diet feeding according to Example 1, the mice before sacrifice were treated with a dual-energy X-ray absorptionmetry (DEXA) using a body fat mass, body fat percentage (fat in tissue) , body composition including lean mass was measured.

Example 5. Statistical processing

The results of this experiment were analyzed using Prism version 8.4.3 (GraphPad Software, Sandiego, CA, USA), and the results of all measurement items were expressed as mean and standard error, and verification of statistical significance between each group was one-way. After confirming the significance by ANOVA, the significance was determined at the level of p < 0.05 using Tukey's test.

Experimental Example 1. Analysis of changes in body weight, dietary intake and dietary efficiency of experimental animals

In order to confirm the weight loss effect of the composition containing celadon 5 of the present invention, the effect of the addition of Daewon soybean and celadon 5 powder on the weight gain of mice consuming a high-fat diet was measured. After 1 week of feeding the experimental diet, the high-fat diet group (HFD) increased in weight compared to the other groups, and after 6 weeks, the weight increased significantly (p < 0.05) by 42.7% compared to the normal diet group (Normal) ( 2).

Referring to FIG. 3 showing the weight loss effect for each group, the high fat-Daewon soybean group (HFD-DW) and the high fat-Celadon No. 5 group (HFD-CJ) significantly (p < 0.05) lost weight compared to the high-fat diet group. In particular, it was confirmed that the high fat-Celadon No. 5 group had a significantly (p < 0.05) lower body weight than the high fat-Daewon bean group, confirming that the Celadon No. 5 of the present study had an excellent weight loss effect.

In addition, the results of weight change, dietary intake, and dietary efficiency after 6 weeks of breeding in the normal diet group, high fat diet group, high fat-daewon bean group, and high fat-celadon 5 group are shown in Table 2.

Results of analysis of food intake, weight change, and dietary efficiency after 6 weeks of breeding (mean ± SEM) process Dietary intake (g/day) Weight change (g) Dietary efficiency (%) normal diet 3.18 ± 0.05 5.89 ± 0.35 4.41 ± 0.26 high fat diet 2.84 ± 0.03 17.89 ± 0.48 15.4 ± 0.39 High Fat - Daewon Beans 2.55 ± 0.23 7.40 ± 0.45 6.43 ± 0.41 High Fat - Celadon No. 5 2.80 ± 0.16 4.23 ± 0.69 3.59 ± 0.57

Looking at the results in Table 2, the high-fat diet group showed the greatest weight gain, with the high-fat diet group showing the weight gain of 17.89 ± 0.64 g over 6 weeks. It was found that the weight gain was lower than that of the high-fat diet group at 0.69 g.

Since dietary intake did not show a significant difference between groups, it was assumed that weight loss was not related to feed intake.

Also, the dietary efficiency was significantly (p < 0.05) lower in the high fat-daewon bean group, high fat-celadon 5 group and normal diet group, compared to 15.4% in the high-fat diet group, especially 3.6% in the high fat-celadon 5 group. showed the lowest dietary efficiency.

As the above effect, it was confirmed that the high fat-celadon group No. 5 had the lowest weight change and low dietary efficiency, and thus had an excellent weight loss effect, which could be usefully used for the treatment, prevention and improvement of metabolic syndrome such as obesity.

Experimental Example 2. Liver weight and epididymal fat weight analysis of experimental animals

As a result of observing the liver of the high-fat diet group immediately after organ extraction according to the method of Example 2, it was confirmed that the liver had a pale red color compared to the normal diet group, and the fat was dispersed to represent a typical fatty liver shape (FIG. 4).

As a result of measuring the liver and epididymal fat weights of each dietary group, as shown in Table 3, the liver weight of the high-fat diet group was 1,406 g, which was significantly (p < 0.05) increased compared to the normal diet group, which was a high-fat diet. It was predicted that the liver was enlarged due to the accumulation of excess fat in the liver. On the other hand, it was confirmed that the liver weights of the high-fat-Daewon Kong group and the high-fat-Celadon No. 5 group were 977.6 and 970.2 g, respectively, significantly (p < 0.05) decreased compared to the high fat diet group.

Results of long-term weight analysis after 6 weeks by taking soybean powder-added feed process Liver weight (mg) Epididymal fat weight (mg) normal diet 1,053 ± 17.6 683.1 ± 51.6 high fat diet 1,406 ± 80.6 2,367 ± 83.6 High Fat - Daewon Beans 977.6 ± 14.9 1,087 ± 65.1 High Fat - Celadon No. 5 970.2 ± 16.3 543.1 ± 40.3

In addition, the weight of epididymal fat in the high fat diet group was 2,367 g, which was significantly (p < 0.05) increased compared to the normal diet group, and the high fat-daewon bean group and high fat-celadon 5 group were 1,087 and 543.1 g, respectively, which were significant compared to the normal diet group. decreased negatively (p < 0.05), confirming the results consistent with the change in weight loss (FIG. 5).

That is, as a result of the above results, Daewon Kong and Cheongja No. 5 showed an effect of reducing fat accumulation in the liver and epididymis due to a high-fat diet, that is, it was confirmed that it was an effective material for treating, preventing and improving metabolic syndrome.

Experimental Example 3. Analysis of blood lipid content in experimental animals

The effect of Daewon soybean and celadon No. 5 on blood lipid content was measured by the method of Example 3, and the results are shown in Table 4.

Results of serum fat-related biomarker analysis after 6 weeks of treatment (mean ± SEM) process TG TC HDL-C normal diet 79.8 ± 3.19 75.1 ± 2.24 78.9 ± 4.35 high fat diet 177 ± 2.26 161 ± 3.20 37.0 ± 3.54 High Fat - Daewon Beans 114 ± 2.94 99.8 ± 2.03 31.0 ± 3.04 High Fat - Celadon No. 5 122 ± 4.26 107 ± 2.85 51.2 ± 6.85

Looking at the above results, the concentration of triglyceride (TG) in the serum was 79.8 mg/dL in the normal diet group, and 177 mg/dL in the high-fat diet group. In the case of the high fat-Daewon bean group and the high fat-Celadon No. 5 group, it was confirmed that it was significantly (p < 0.05) lower than that of the high fat diet group at 114 and 122 mg/dL, respectively.

In addition, the content of total cholesterol (total cholesterol, TC) was also significantly (p < 0.05) decreased in the high fat-Daewon soybean group and the high fat-Celadon No. 5 group compared to the high-fat diet group, confirming the blood cholesterol reduction effect.

As a result, it can be confirmed that Celadon No. 5 of the present application shows an excellent effect in the treatment, prevention and improvement of metabolic syndrome due to the blood lipid improvement effect by showing the effect of reducing the content of triglycerides and cholesterol in the blood increased by the high-fat diet. there was.

Experimental Example 4. Analysis of liver function indicators of experimental animals

The liver function index was analyzed by the method of Example 3. Aspartate transaminase (AST) and alanine transaminase (ALT), which are indicators of liver function, are abundantly distributed in the liver and heart, and their concentrations increase when hepatocytes are damaged, so AST and ALT levels in the blood can be indicators of liver damage.

Results of analysis of indicators of improvement in liver function after 6 weeks of treatment process AST (IU/L) ALT (IU/L) normal diet 7.59 ± 1.13 4.41 ± 0.26 high fat diet 8.72 ± 0.37 15.4 ± 0.39 High Fat - Daewon Beans 7.98 ± 0.91 6.43 ± 0.41 High Fat - Celadon No. 5 6.85 ± 0.40 3.59 ± 0.57

As a result, as shown in Table 5 above, the AST enzyme of the high-fat diet group, which exhibited fatty liver due to the high-fat diet, showed a high value of 8.72 IU/L, and 7.98 and 6.85 IU in the high-fat-daewonkong group and high-fat-celadon 5 group, respectively. /L was confirmed to be lowered.

In addition, it was confirmed that the ALT concentration of the high fat diet group was significantly (p < 0.05) lowered to 6.43 and 3.59 IU/L in the high fat-daewon bean group and the high fat-celadon 5 group, respectively, compared to 15.4 IU/L in the high fat diet group, and AST and The normal range of ALT level was 40 IU/L or less, and it was confirmed that the AST and ALT levels of all groups were within the normal range.

Therefore, as a result, it was confirmed that the intake of Daewon soybean and celadon No. 5 exerted the effect of improving liver function.

Experimental Example 5. Analysis of fasting blood glucose in experimental animals

The results of analyzing the fasting blood glucose of the experimental animals according to the method of Example 2 are shown in FIG. 6 .

6, the high-fat diet group showed 44.1% higher blood sugar than the normal diet group, and the high-fat-Daewon bean group and the high-fat-Cheongja No. 5 group were 34.2 and 46.6% significantly higher than the high-fat diet group, respectively (p < 0.05). decrease could be observed.

That is, it was confirmed that Celadon No. 5 has the effect of treating, preventing and improving metabolic syndrome by reducing the rise in blood sugar caused by diseases such as obesity and diabetes.

Experimental Example 6. Body composition of experimental animals (body composition) analysis

According to the method of Example 4, using a dual-energy X-ray absorptionmetry (DEXA) of experimental animals of group 4, fat mass, fat in tissue, lean mass ) was measured, and the results are shown in FIGS. 7 and 8 .

As a result, the percentage of body fat decreased significantly (p < 0.05) by 34.4 and 54.6% in the high-fat-Daewon bean group and the high-fat-Celadon 5 group, respectively, compared to the high-fat diet group. It was confirmed that there was a significant (p < 0.05) increase of 22.8 and 35.4% in the Daewon Kong group and the high fat-celadon No. 5 group, respectively.

Through this, it was confirmed that the weight loss effect of Celadon No. 5 was due to the reduction in body fat weight, and as a result of the above results, it was confirmed that Celadon No. 5 had an excellent effect on metabolic syndrome including obesity due to increased body fat.

Experimental Example 7. Comparison of functional ingredients by bean variety

Anthocyanins were dispensed in a solvent mixed with 20% methanol and 1% HCL in 0.1 g of black soybean skin sample, passed through a 0.2 μm filter, and analyzed by HPLC. A Thermo UHPLC Ultimate 3000 instrument was used, and a YMC Triart C-18 column was used. As solvents, water and methanol were used. It was analyzed with a UV detector 530 nm.

Isoflavones were analyzed by HPLC by stirring and extracting 1 g of a soybean pulverized sample in a 50% methanol solvent. A Thermo UHPLC Ultimate 3000 instrument was used, and a Lichrospher RPC18 column was used. Water and acetonitrile solvent were used, and analysis was performed with a UV detector.

Polyphenols were extracted with stirring in 80% ethanol, mixed with 10% Folin-Ciocalteu reagent, left for 5 minutes, 7.5% Na ₂ CO ₃ was added, stored in a dark place for 2 hours, and colorimetric quantification was performed at 750 nm. The results are shown using gallic acid (GA) as a standard material.

For DPPH, the extract obtained by stirring the pulverized sample in 80% ethanol was added to a 0.2 mM DPPH solution, and absorbance was measured at 520 nm. Trolox was used as a standard and the results were shown.

ABTS is an extract obtained by stirring and extracting a pulverized sample in 80% ethanol, mixing ABTS and potassium persulphate in a 1:1 ratio and leaving it in a dark place at room temperature for 12 to 16 hours to form ABTS cations. After dilution with ethanol to ±0.2, the extract was added to the diluted ABTS solution, and absorbance was measured at 735 nm.

According to the above method, the functional ingredients of Cheongja No. 5, a soybean variety of the present application, are shown in Table 6 in comparison with other varieties.

('18-'19, Miryang) breed name anthocyanins
(μg/g seed coat) isoflavones
(μg/g) polyphenols
(mgGAE/100g) ABTS ¹⁾
(mgTE/100g) DPPH ¹⁾
(mgTE/100g) Celadon No. 5 22,704a ²⁾ 3,111a 238.5a 471.2a 263.1a Celadon No. 3 15,568b 1,730b 200.5b 423.9b 231.2b native species 8,564c 2,252b 206.9b 417.2b 232.3b

1) ABTS, DPPH: The degree to which free radicals that cause aging are decomposed by antioxidants

2) There is a significant difference between varieties when the alphabet is different (Duncan's multiple range test result, p < 0.05)

As can be seen in Table 6, it was confirmed that the soybean variety of the present application, Celadon No. 5, contained significantly more anthocyanin content compared to Celadon No. 3 or the conventional variety (Seoritae), and the content of isoflavones and polyphenols was also higher than that of other varieties. It was found to have excellent antioxidant activity.

Therefore, the soybean variety of the present application, celadon No. 5, has superior functionality compared to other existing soybean varieties and has excellent effects in preventing, treating and improving metabolic syndrome-related diseases, so it can be usefully used in medicines, foods, and health functional foods using the same. confirmed that there is.

From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the examples described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the claims described below and their equivalents.

Claims (8)

A pharmaceutical composition for the prevention or treatment of metabolic syndrome-related diseases comprising soybean variety Celadon No. 5 as an active ingredient.
The composition of claim 1, wherein the metabolic syndrome-related disease is obesity, hypertension, fatty liver, diabetes, dyslipidemia, hyperlipidemia, or arteriosclerosis.
The composition of claim 1, wherein the soybean variety Celadon No. 5 is a Celadon No. 5 plant, its seeds, a dried product of the seed, an extract of the seed, or a fraction thereof.
The composition according to claim 1, wherein the composition is due to the effect of reducing the weight reduction, blood sugar rise, blood lipid improvement, cholesterol content reduction, liver function improvement, and epididymal tissue fat accumulation reduction or body fat weight reduction effect of soybean variety Celadon No. 5 .
A method for preventing or treating metabolic syndrome-related diseases, comprising administering the composition of any one of claims 1 to 4 to a non-human subject.
A health functional food composition for preventing or improving metabolic syndrome-related diseases, comprising bean variety celadon No. 5 as an active ingredient.
A quasi-drug composition for preventing or improving metabolic syndrome-related diseases comprising bean variety Celadon No. 5 as an active ingredient.
A feed composition for preventing or improving metabolic syndrome-related diseases comprising bean variety celadon No. 5 as an active ingredient.

Images